Statins and diabetes risk: How real is it and what are the mechanisms?

Current Opinion in Pediatrics

Volumn 26, Issue 3, 2015, Pages 228-235

  Robinson, Jennifer G ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

cardiovascular risk; diabetes; statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADIPOCYTE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; DIABETES MELLITUS; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN; GENETIC POLYMORPHISM; HYPERCHOLESTEROLEMIA; ANIMAL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; GENETICS; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 84957884318     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000172     Document Type: Review

References (31)

1. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-362.
2. Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
3. Rajpathak S, Kumbhani D, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-1929.
4. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
5. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556-2564.
6. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2014; 113:1753-1764.
7. Danaei G, Garcá Rodŕguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013; 36:1236-1240.
8. Ko DT, Wijeysundera HC, Jackevicius CA, et al. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circulation 2013; 6:315-322.
9. Wang K-L, Liu C-J, Chao T-F, et al. Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. Am J Cardiol 2014; 113:631-636.
10. Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014; 348:g3244.
11. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013; 23:; 2013-05-23 2331-42;346:f2610.
12. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61:148-152.
13. Ong K-L, Waters DD, Messig M, et al. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the Treating to New Targets Study). Am J Cardiol 2014; 113:1593-1598.
14. Shen L, Shah BR, Reyes EM, et al. Role of diuretics, b blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 2013; 11:; 2013-12-09 11:39:39;347:f6745.
15. Brault M, Ray J, Gomez Y-H, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014; 63:735-745.
16. Koh K, Quon M, Han S, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55:1209-1216.
17. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385:351-361.
18. Henriksbo BD, Lau TC, Cavallari JF, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014; 63:3742-3747.
19. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in nondiabetics: a systematic review and meta-analysis. Diab Res Clin Pract 2010; 87:98-107.
20. Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diab Care 2014; 37:2225-2232.
21. Nielsen S, Nordestgaard B. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol 2014; 2:894-900.
22. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Part B):2889-2934.
23. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380:565-571.
24. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590.
25. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Part B):2960-2984.
26. Perreault L, Temprosa M, Mather KJ, et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. Diab Care 2014; 37:2622-2631.
27. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63 (25 Part B): 2985-3023.
28. Panz V, Immelman A, Paiker J, et al. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab Syndr Relat Disord 2012; 10:351-357.
29. Skoumas J, Liontou C, Chrysohoou C, et al. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 2014; 237:140-145.
30. Ter Avest E, Abbink EJ, De Graaf J, et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005; 35:558-564.
31. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. JAMA 2014; 311:1870-1882.